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The placebo response plays a major role in psychiatry, particularly in depression. A new network meta-analysis investigates
whether the effects of placebo vary in studies comparing fluoxetine and venlafaxine, two widely prescribed antidepressants.
Even though data from this article indicate that the effects of placebos do not differ, publication bias cannot be ruled out.
The authors use their finding to criticise the paradigm of evidence-based medicine, questioning whether there is anything
certain in psychiatry and, more precisely, in the field of antidepressant treatment for major depression. This study
stimulates the debate about validity of scientific knowledge in medicine and highlights the importance of considering
things from a different perspective. However, the authors’ view should be considered with caution. As clinicians, we make
decisions every day, integrating individual clinical expertise and patients’ preferences and values with the best, up-to-date
research data. The quality of scientific information must be improved, but we still think that valid conclusions to help
clinical practice can be drawn from a critical and cautious use of the best available, if flawed, evidence.
Please see related articles: http://www.biomedcentral.com/1741-7015/11/230 and http://www.biomedcentral.com/1741-
7015/12/106.
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The placebo effect has always been an intriguing topic in
medicine, probably because of both its clinical implica-
tions and its philosophical correlates for the mind-body
interaction [1]. From a scientific point of view, our know-
ledge of the biological mechanisms for response to pla-
cebo has recently increased, thanks to more rigorous and
systematic investigations [2]. Accumulating evidence sug-
gests that the placebo effect is a genuine psychobiological
phenomenon attributable to the overall therapeutic con-
text, which includes the interaction between the patient,
the clinician and the treatment environment [3].
The placebo effect has been explored across a variety of
diseases and medical conditions but it is in psychiatry -
and most of all in depression - that the placebo response
may play a major clinical role. This has generated con-
cerns and a long-lasting debate around the real efficacy of* Correspondence: andrea.cipriani@psych.ox.ac.uk
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2014antidepressants, with very conflicting opinions [4,5]. In
antidepressant trials with adults, the mean response rate
for active treatment is 50%, while the mean placebo re-
sponse is 31%, with an absolute difference of 19% [6]. This
difference is even smaller if unpublished data are included
in the analysis [7] or if special populations, like children
and adolescents, are considered [8]. Interestingly, the pla-
cebo response has been increasing over the past 30 years
and this increase does not appear to be directly explained
by changes in study characteristics [6]. The real question,
then, is not whether the placebo effect can influence clin-
ical outcome but rather the extent to which it does so. A
study by Naudet et al. published in BMC Medicine inves-
tigates this issue within the frame of a network meta-
analysis [9].Study results
Accepting that randomized evidence shows both antide-
pressants and placebo to be effective in major depres-
sion, and that different antidepressants have differentCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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whether the effects of placebo may vary in different sit-
uations [9]. As acknowledged by the authors, this is
more an epistemological question than a pragmatic clin-
ical issue. However, Naudet and colleagues approached
it scientifically and performed a review of the literature
comparing the placebos of two widely prescribed anti-
depressants: fluoxetine and venlafaxine.
Their primary aim was to compare placebo arms in flu-
oxetine and venlafaxine placebo-controlled studies, so the
authors looked at three different types of placebo: fluoxet-
ine placebo (in studies where placebo was compared to
fluoxetine), venlafaxine placebo (where placebo was com-
pared to venlafaxine), and fluoxetine/venlafaxine placebo
(where placebo was compared in the same trial with both
venlafaxine and fluoxetine). The authors find that the two
antidepressant agents are more efficacious than the place-
bos and the three placebos do not differ in terms of re-
sponse or remission. As has been previously reported,
venlafaxine is more efficacious than fluoxetine, but the
funnel plots show some evidence of publication bias.
Emphasising this last point - and almost neglecting the
primary finding of no difference between placebos - Naudet
and colleagues argue that no one can be sure placebo
really equals placebo in trials of major depressive disorder.
Following this theoretical reasoning, they warn clinicians
to ‘step back to take a more objective view when interpret-
ing a scientific result’, because ‘Science can never be actu-
ally sure that “sucrose = sucrose” in the treatment of major
depressive disorder’. For Naudet and colleagues, these
clinical implications are more important than the differ-
ences in efficacy between antidepressants (which, in our
view, is much more likely and clinically very meaningful).
Strengths and limitations of the study
The main strength of this paper is the authors’ attempt
to look at this clinical scenario in a novel way. Scientific
knowledge in medicine can progress only when people
try to see things from a different perspective, pursuing
the truth and avoiding easy answers [10].
The primary results from this study are consistent
with evidence on antidepressants in moderate to severe
acute major depression: some antidepressants are more
effective than placebo [11] and material differences in ef-
ficacy exist between these drugs [12]. The clinical inter-
pretation of these findings may vary [13] and it is worth
remembering that the practice of evidence-based medi-
cine implies the integration of the best available research
data with individual clinical expertise and patients’ pref-
erences and values [14]. Evidence-based practice is not
‘cookbook’ medicine and, similarly, ranking antidepres-
sants is not aimed at providing clinicians and patients
with a list of drugs to mechanically scroll down from top
to bottom. The crucial point is whether to insist on aconservative approach that considers antidepressants as a
group of equivalent compounds (thus favouring the pre-
scription of the last one put on the market) or to try to
make the best use of the available evidence. We still think
that valid conclusions can be drawn from a critical and
cautious use of the best available, if flawed, evidence.
Currently, placebos are not an alternative for our pa-
tients when an antidepressant is indicated for moderate to
severe depression. In such cases, we all prescribe an active
treatment. However, when discussing the treatment plan
with our patients, it would be wrong and probably clinic-
ally irresponsible to say that antidepressants are all the
same and to give our patients any antidepressant, just be-
cause it is licensed and the side-effect profile is more suit-
able for that individual. There is evidence supporting that
some drugs licensed for depression are clearly less effect-
ive than others [12] and that some do not differ from pla-
cebo [15]. Even though the decisional process varies case
by case and we may end up making a completely different
choice, as clinical researchers this is the best information
we can give to help patients and clinicians when an anti-




Scientific interest is focusing on the influence of the pla-
cebo response on signal detection in clinical trials and
what its physiologic mechanisms reveal about the patho-
physiology of major depressive disorder [16]. High placebo
response has reduced medication-placebo differences and
the increasing number of failed trials has contributed to re-
cent decisions by several pharmaceutical companies to dis-
continue research on medications for brain disorders [17].
The development of psychiatric medications has become
progressively more time-consuming and more expensive
[18]. The need for placebo superiority for regulatory ap-
proval is a matter of controversy, but it is still the rule for
many regulatory agencies [19]. This is why the evaluation
of future, putative antidepressant agents should require a
minimisation of placebo response, the development of
more efficient study designs to improve signal detection in
drug development studies, and an increased antidepressant
response in clinical treatment [16].
For clinicians
In psychiatry, pharmacological treatment involves much
more than simply dispensing pills, so prescribing a pla-
cebo does not mean that the patient receives no treat-
ment at all [16]. The expectation of improvement and
contact with a health-care environment with supportive
and therapeutic features contribute in a probably signifi-
cant proportion to the responses observed in rando-
mised controlled trials to both medication and placebo
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ical management in clinical trial settings are usually not
provided to the same extent in standard clinical practice.
While avoiding the least effective antidepressants already
available, clinicians should also combine active medica-
tion with a specific context and level of therapeutic con-
tact, to enhance non-specific effects of treatment and
gain greater treatment response.
For study authors and journal editors
Systematic reviews and meta-analyses should be consid-
ered as scientific work, because they produce new know-
ledge [21] and, by definition, their findings and results
are replicable. For this reason, all data should be pub-
lished in the article, with figures and denominators to
allow re-analysis of the data. This transparency is needed
at all levels: regulatory agencies, pharmaceutical indus-
tries, scientific journals and also researchers [22]. In the
review by Naudet et al., forest plots were originally re-
ported without event rates, and a proper table with the
characteristics of included studies and corresponding
references was missing. Thanks to our commentary and
the journal editor’s help, the authors have now provided
the requested information and data in a comment pub-
lished in BMC Medicine [23].
As researchers, we need to improve the quality of sci-
entific information and keep seeking the truth; at the
same time, though, as clinicians we need to reject either
too simplistic approaches or ideological nihilism.
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